Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C15H18N8O5.H2O |
Molecular Weight | 408.3693 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.CNC(=O)C1=CN(N=C1)C2=NC3=C(N=CN3[C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)C(N)=N2
InChI
InChIKey=CDQVVPUXSPZONN-WPPLYIOHSA-N
InChI=1S/C15H18N8O5.H2O/c1-17-13(27)6-2-19-23(3-6)15-20-11(16)8-12(21-15)22(5-18-8)14-10(26)9(25)7(4-24)28-14;/h2-3,5,7,9-10,14,24-26H,4H2,1H3,(H,17,27)(H2,16,20,21);1H2/t7-,9-,10-,14-;/m1./s1
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001176/WC500097103.pdf | https://ec.europa.eu/health/documents/community-register/2014/20140116127516/anx_127516_en.pdf | https://www.drugs.com/ppa/regadenoson.html
Curator's Comment: description was created based on several sources, including:
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001176/WC500097103.pdf | https://ec.europa.eu/health/documents/community-register/2014/20140116127516/anx_127516_en.pdf | https://www.drugs.com/ppa/regadenoson.html
Regadenoson (Lexiscan), a low affinity agonist of the A2A adenosine receptor, increases coronary blood flow (CBF) and mimics the increase in CBF caused by exercise. Myocardial uptake of the radiopharmaceutical is proportional to CBF creating the contrast required to identify stenotic coronary arteries. It is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress. The most common adverse reactions to Lexiscan are dyspnea, headache, flushing, chest discomfort, dizziness, angina pectoris, chest pain, and nausea. Methylxanthines, e.g., caffeine and theophylline, may interfere with the activity of Lexiscan. Aminophylline may be used to attenuate severe and/or persistent adverse reactions to Lexiscan.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL226 |
16.0 µM [Ki] | ||
Target ID: CHEMBL251 |
1.3 µM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | LEXISCAN Approved UseLexiscan® (regadenoson) injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress. Lexiscan is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress (1). Launch Date2008 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
13.6 ng/mL |
400 μg single, intravenous dose: 400 μg route of administration: Intravenous experiment type: SINGLE co-administered: |
REGADENOSON plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
11.7 ng × h/mL |
400 μg single, intravenous dose: 400 μg route of administration: Intravenous experiment type: SINGLE co-administered: |
REGADENOSON plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2 h |
400 μg single, intravenous dose: 400 μg route of administration: Intravenous experiment type: SINGLE co-administered: |
REGADENOSON plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
30 ug/kg single, intravenous Highest studied dose Dose: 30 ug/kg Route: intravenous Route: single Dose: 30 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Other AEs: Chest pain, Palpitation... Other AEs: Chest pain (1 patient) Sources: Page: 1211Palpitation (3 patients) Flushing (3 patients) Shortness of breath (4 patients) Nausea and vomiting (5 patients) Change in ECG (1 patient) Headache (4 patients) |
10 ug/kg single, intravenous MTD Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in standing position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Other AEs: Chest pain, Palpitation... Other AEs: Chest pain (1 patient) Sources: Page: 1211Palpitation (3 patients) Dizziness (3 patients) Shortness of breath (1 patient) Nausea and vomiting (2 patients) Headache (3 patients) |
10 ug/kg single, intravenous MTD Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Other AEs: Palpitation, Dizziness... Other AEs: Palpitation (4 patients) Sources: Page: 1211Dizziness (2 patients) Flushing (4 patients) Shortness of breath (2 patients) Change in ECG (1 patient) Headache (1 patient) |
20 ug/kg single, intravenous MTD Dose: 20 ug/kg Route: intravenous Route: single Dose: 20 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in standing position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Other AEs: Chest pain, Palpitation... Other AEs: Chest pain (2 patients) Sources: Page: 1211Palpitation (2 patients) Dizziness (3 patients) Flushing (1 patient) Nausea and vomiting (4 patients) Headache (3 patients) |
20 ug/kg single, intravenous MTD Dose: 20 ug/kg Route: intravenous Route: single Dose: 20 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Other AEs: Chest pain, Palpitation... Other AEs: Chest pain (1 patient) Sources: Page: 1211Palpitation (4 patients) Dizziness (3 patients) Flushing (8 patients) Shortness of breath (3 patients) Nausea and vomiting (3 patients) Change in ECG (7 patients) Headache (7 patients) |
3 ug/kg single, intravenous Recommended Dose: 3 ug/kg Route: intravenous Route: single Dose: 3 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in standing position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Other AEs: Palpitation, Dizziness... Other AEs: Palpitation (2 patients) Sources: Page: 1211Dizziness (1 patient) Flushing (1 patient) Change in ECG (3 patients) |
3 ug/kg single, intravenous Recommended Dose: 3 ug/kg Route: intravenous Route: single Dose: 3 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Other AEs: Chest pain, Palpitation... Other AEs: Chest pain (1 patient) Sources: Page: 1211Palpitation (2 patients) Dizziness (1 patient) Flushing (3 patients) Shortness of breath (1 patient) Change in ECG (1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Change in ECG | 1 patient | 30 ug/kg single, intravenous Highest studied dose Dose: 30 ug/kg Route: intravenous Route: single Dose: 30 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Chest pain | 1 patient | 30 ug/kg single, intravenous Highest studied dose Dose: 30 ug/kg Route: intravenous Route: single Dose: 30 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Flushing | 3 patients | 30 ug/kg single, intravenous Highest studied dose Dose: 30 ug/kg Route: intravenous Route: single Dose: 30 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Palpitation | 3 patients | 30 ug/kg single, intravenous Highest studied dose Dose: 30 ug/kg Route: intravenous Route: single Dose: 30 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Headache | 4 patients | 30 ug/kg single, intravenous Highest studied dose Dose: 30 ug/kg Route: intravenous Route: single Dose: 30 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Shortness of breath | 4 patients | 30 ug/kg single, intravenous Highest studied dose Dose: 30 ug/kg Route: intravenous Route: single Dose: 30 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Nausea and vomiting | 5 patients | 30 ug/kg single, intravenous Highest studied dose Dose: 30 ug/kg Route: intravenous Route: single Dose: 30 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Chest pain | 1 patient | 10 ug/kg single, intravenous MTD Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in standing position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Shortness of breath | 1 patient | 10 ug/kg single, intravenous MTD Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in standing position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Nausea and vomiting | 2 patients | 10 ug/kg single, intravenous MTD Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in standing position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Dizziness | 3 patients | 10 ug/kg single, intravenous MTD Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in standing position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Headache | 3 patients | 10 ug/kg single, intravenous MTD Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in standing position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Palpitation | 3 patients | 10 ug/kg single, intravenous MTD Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in standing position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Change in ECG | 1 patient | 10 ug/kg single, intravenous MTD Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Headache | 1 patient | 10 ug/kg single, intravenous MTD Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Dizziness | 2 patients | 10 ug/kg single, intravenous MTD Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Shortness of breath | 2 patients | 10 ug/kg single, intravenous MTD Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Flushing | 4 patients | 10 ug/kg single, intravenous MTD Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Palpitation | 4 patients | 10 ug/kg single, intravenous MTD Dose: 10 ug/kg Route: intravenous Route: single Dose: 10 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Flushing | 1 patient | 20 ug/kg single, intravenous MTD Dose: 20 ug/kg Route: intravenous Route: single Dose: 20 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in standing position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Chest pain | 2 patients | 20 ug/kg single, intravenous MTD Dose: 20 ug/kg Route: intravenous Route: single Dose: 20 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in standing position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Palpitation | 2 patients | 20 ug/kg single, intravenous MTD Dose: 20 ug/kg Route: intravenous Route: single Dose: 20 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in standing position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Dizziness | 3 patients | 20 ug/kg single, intravenous MTD Dose: 20 ug/kg Route: intravenous Route: single Dose: 20 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in standing position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Headache | 3 patients | 20 ug/kg single, intravenous MTD Dose: 20 ug/kg Route: intravenous Route: single Dose: 20 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in standing position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Nausea and vomiting | 4 patients | 20 ug/kg single, intravenous MTD Dose: 20 ug/kg Route: intravenous Route: single Dose: 20 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in standing position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Chest pain | 1 patient | 20 ug/kg single, intravenous MTD Dose: 20 ug/kg Route: intravenous Route: single Dose: 20 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Dizziness | 3 patients | 20 ug/kg single, intravenous MTD Dose: 20 ug/kg Route: intravenous Route: single Dose: 20 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Nausea and vomiting | 3 patients | 20 ug/kg single, intravenous MTD Dose: 20 ug/kg Route: intravenous Route: single Dose: 20 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Shortness of breath | 3 patients | 20 ug/kg single, intravenous MTD Dose: 20 ug/kg Route: intravenous Route: single Dose: 20 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Palpitation | 4 patients | 20 ug/kg single, intravenous MTD Dose: 20 ug/kg Route: intravenous Route: single Dose: 20 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Change in ECG | 7 patients | 20 ug/kg single, intravenous MTD Dose: 20 ug/kg Route: intravenous Route: single Dose: 20 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Headache | 7 patients | 20 ug/kg single, intravenous MTD Dose: 20 ug/kg Route: intravenous Route: single Dose: 20 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Flushing | 8 patients | 20 ug/kg single, intravenous MTD Dose: 20 ug/kg Route: intravenous Route: single Dose: 20 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Dizziness | 1 patient | 3 ug/kg single, intravenous Recommended Dose: 3 ug/kg Route: intravenous Route: single Dose: 3 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in standing position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Flushing | 1 patient | 3 ug/kg single, intravenous Recommended Dose: 3 ug/kg Route: intravenous Route: single Dose: 3 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in standing position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Palpitation | 2 patients | 3 ug/kg single, intravenous Recommended Dose: 3 ug/kg Route: intravenous Route: single Dose: 3 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in standing position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Change in ECG | 3 patients | 3 ug/kg single, intravenous Recommended Dose: 3 ug/kg Route: intravenous Route: single Dose: 3 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in standing position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Change in ECG | 1 patient | 3 ug/kg single, intravenous Recommended Dose: 3 ug/kg Route: intravenous Route: single Dose: 3 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Chest pain | 1 patient | 3 ug/kg single, intravenous Recommended Dose: 3 ug/kg Route: intravenous Route: single Dose: 3 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Dizziness | 1 patient | 3 ug/kg single, intravenous Recommended Dose: 3 ug/kg Route: intravenous Route: single Dose: 3 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Shortness of breath | 1 patient | 3 ug/kg single, intravenous Recommended Dose: 3 ug/kg Route: intravenous Route: single Dose: 3 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Palpitation | 2 patients | 3 ug/kg single, intravenous Recommended Dose: 3 ug/kg Route: intravenous Route: single Dose: 3 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Flushing | 3 patients | 3 ug/kg single, intravenous Recommended Dose: 3 ug/kg Route: intravenous Route: single Dose: 3 ug/kg Sources: Page: 1211 |
healthy, 18-50 years n = 4 Health Status: healthy Condition: in supine position Age Group: 18-50 years Sex: M Population Size: 4 Sources: Page: 1211 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 8.0 |
no | |||
Page: 8.0 |
no | |||
Page: 8.0 |
no | |||
Page: 8.0 |
no | |||
Page: 8.0 |
no | |||
Page: 8.0 |
no | |||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 4.0 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.astellas.us/docs/lexiscan.pdf
5 mL (0.4 mg) by rapid injection; followed immediately by saline flush and
radiopharmaceutical.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26626489
10 nM CVT-3146 decreased coronary perfusion pressure by 23 mm Hg in rat isolated perfused heart.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175788
Created by
admin on Fri Dec 15 16:12:17 GMT 2023 , Edited by admin on Fri Dec 15 16:12:17 GMT 2023
|
||
|
WHO-ATC |
C01EB21
Created by
admin on Fri Dec 15 16:12:17 GMT 2023 , Edited by admin on Fri Dec 15 16:12:17 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
RAPISCAN (AUTHORIZED: MYOCARDIAL PERFUSION IMAGING)
Created by
admin on Fri Dec 15 16:12:17 GMT 2023 , Edited by admin on Fri Dec 15 16:12:17 GMT 2023
|
||
|
NCI_THESAURUS |
C29707
Created by
admin on Fri Dec 15 16:12:17 GMT 2023 , Edited by admin on Fri Dec 15 16:12:17 GMT 2023
|
||
|
WHO-VATC |
QC01EB21
Created by
admin on Fri Dec 15 16:12:17 GMT 2023 , Edited by admin on Fri Dec 15 16:12:17 GMT 2023
|
||
|
NDF-RT |
N0000178375
Created by
admin on Fri Dec 15 16:12:17 GMT 2023 , Edited by admin on Fri Dec 15 16:12:17 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL317052
Created by
admin on Fri Dec 15 16:12:17 GMT 2023 , Edited by admin on Fri Dec 15 16:12:17 GMT 2023
|
PRIMARY | |||
|
5596
Created by
admin on Fri Dec 15 16:12:17 GMT 2023 , Edited by admin on Fri Dec 15 16:12:17 GMT 2023
|
PRIMARY | |||
|
C430916
Created by
admin on Fri Dec 15 16:12:17 GMT 2023 , Edited by admin on Fri Dec 15 16:12:17 GMT 2023
|
PRIMARY | |||
|
Regadenoson
Created by
admin on Fri Dec 15 16:12:17 GMT 2023 , Edited by admin on Fri Dec 15 16:12:17 GMT 2023
|
PRIMARY | |||
|
DB06213
Created by
admin on Fri Dec 15 16:12:17 GMT 2023 , Edited by admin on Fri Dec 15 16:12:17 GMT 2023
|
PRIMARY | |||
|
m9517
Created by
admin on Fri Dec 15 16:12:17 GMT 2023 , Edited by admin on Fri Dec 15 16:12:17 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID70236374
Created by
admin on Fri Dec 15 16:12:17 GMT 2023 , Edited by admin on Fri Dec 15 16:12:17 GMT 2023
|
PRIMARY | |||
|
44154280
Created by
admin on Fri Dec 15 16:12:17 GMT 2023 , Edited by admin on Fri Dec 15 16:12:17 GMT 2023
|
PRIMARY | |||
|
2362
Created by
admin on Fri Dec 15 16:12:17 GMT 2023 , Edited by admin on Fri Dec 15 16:12:17 GMT 2023
|
PRIMARY | |||
|
875148-45-1
Created by
admin on Fri Dec 15 16:12:17 GMT 2023 , Edited by admin on Fri Dec 15 16:12:17 GMT 2023
|
PRIMARY | |||
|
640062
Created by
admin on Fri Dec 15 16:12:17 GMT 2023 , Edited by admin on Fri Dec 15 16:12:17 GMT 2023
|
PRIMARY | RxNorm | ||
|
TT-01
Created by
admin on Fri Dec 15 16:12:17 GMT 2023 , Edited by admin on Fri Dec 15 16:12:17 GMT 2023
|
PRIMARY | |||
|
100000115275
Created by
admin on Fri Dec 15 16:12:17 GMT 2023 , Edited by admin on Fri Dec 15 16:12:17 GMT 2023
|
PRIMARY | |||
|
REGADENOSON
Created by
admin on Fri Dec 15 16:12:17 GMT 2023 , Edited by admin on Fri Dec 15 16:12:17 GMT 2023
|
PRIMARY | |||
|
2XLN4Y044H
Created by
admin on Fri Dec 15 16:12:17 GMT 2023 , Edited by admin on Fri Dec 15 16:12:17 GMT 2023
|
PRIMARY | |||
|
C74420
Created by
admin on Fri Dec 15 16:12:17 GMT 2023 , Edited by admin on Fri Dec 15 16:12:17 GMT 2023
|
PRIMARY | |||
|
2XLN4Y044H
Created by
admin on Fri Dec 15 16:12:17 GMT 2023 , Edited by admin on Fri Dec 15 16:12:17 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD